（来源：千龙网） 来自农工党界别的市政协委员、北京安贞医院双心医学中心主任刘梅颜建议，加强智慧医疗网络体系建 设，以远程医疗监测为基础，建立定期双心（心脏和心理）体检机制，加强双心医学学科建设。 刘梅颜长期工作在临床一线。她说，精神压力也会诱发心脏损伤和心理健康问题，"对双心健康问题的 长期监测和早期筛查发现尤其重要。"刘梅颜建议，可以根据心脏超声、心电图等数据，建立疾病数据 库，深入研究发病机制等，建立风险评估体系。在此基础上，专家团队要对存在健康风险的人群进行远 程咨询和心理疏导，形成个性化治疗方案。 刘梅颜还建议，集中北京双心优势资源，打通心血管和精神、心理、内分泌、睡眠等学科之间的通道， 加强双心医学学科建设，促进医院普遍开设双心门诊和双心病房。 ...

Core Viewpoint - Microelectrophysiology announced the transfer of 36.3636% equity in its associate company Shanghai Yuanchin Medical Technology Co., Ltd. to Shanghai Mohua Artificial Intelligence Technology Co., Ltd. for a transaction price of RMB 5 million, after which the company will no longer hold shares in Shanghai Yuanchin [1][6] Company Overview - Microelectrophysiology was established on August 31, 2010, in the Shanghai International Medical Park, focusing on innovative medical device research, production, and sales in the field of electrophysiological intervention and ablation therapy [3][8] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation therapy centered on precise interventional navigation, having completed a comprehensive product layout covering cardiac electrophysiology surgery [3][8] Financial Performance of Shanghai Yuanchin - Shanghai Yuanchin has invested over RMB 40 million in R&D and holds multiple patents and product registration certificates, but has been in a continuous loss state due to challenges in hospital promotion and intense market competition [4][9] - The projected net loss for Shanghai Yuanchin is RMB 4.594 million for 2024, and RMB 2.9725 million for the period from January to October 2025, with a net asset value of -RMB 8.0792 million as of October 31, 2025 [4][9] Strategic Intent - The transfer of shares is aimed at optimizing the asset structure and focusing on core business areas, with Shanghai Mohua's business highly compatible with Shanghai Yuanchin's technology services and software development, potentially providing industrial resource empowerment [5][10]